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ABSTRACT 
The Class II Transactivator (CIITA), is the master regulator of Major Histocompatibility Class II 
(MHC II) genes. Transcription of CIITA is characterized by a decrease in specific trimethylation of histone 
H3 lysine 27 (H3K27me3), catalyzed by the histone methyltransferase Enhancer of Zeste Homolog 2 
(EZH2). While EZH2 is the known catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) and is 
present at the inactive CIITA promoter; the mechanisms of recruitment of PRC2 to mammalian promot-
ers remains unknown. Here we identify two DNA-binding proteins, YY1 and Jarid2, which interact with 
and regulate PRC2 recruitment to CIITA promoters. Our study is the first to identify novel roles of YY1 
and Jarid2 in the epigenetic regulation of a mammalian gene by the PRC2. 
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1     INTRODUCTION  
1.1 Epigenetics and Histone Modifications 
A complete genome is an organismal blueprint which contains the necessary genes that encode 
proteins to produce a functioning organism. For appropriate gene expression to occur, chromatin must 
be regulated through reversible, dynamic changes [2, 3]. Epigenetics is a rapidly expanding field that 
studies heritable changes in gene expression that are controlled at the level of transcription by mecha-
nisms other than DNA sequence alteration [4]. Three main epigenetic control mechanisms of gene ex-
pression include: DNA methylation, post-translational modifications (PTMs) of histones, and non-coding 
RNA based interactions [5]. The focal point of this study is on the regulation of a gene through histone 
modifying enzymes. 
The eukaryotic cell contains large amounts of highly condensed nuclear DNA. Condensed DNA, 
or chromatin, is highly structured with multiple orders of condensation. Epigenetic studies currently fo-
cus on the “beads on a string” model of chromatin structure (Figure 1) which consist of DNA tightly 
wrapped one and a half times around nucleosomes [6]. Nucleosomes are multi-protein complexes com-
posed of individual subunit proteins called histones which are highly conserved across eukaryotic spe-
cies [7]. There are five types of histones designated as H1, H2A, H2B, H3 and H4 [8]. The nucleosome 
core forms an octamer containing 2 dimers each of H3/H4 [9, 10] and H2A/H2B [11]. H1 serves as a sta-
bilizer of the linker DNA which is wrapped around the nucleosome core [12-14]. Each of these histone 
proteins has an N-terminal tail extending from the core nucleosome structure [15, 16] which interacts 
with DNA and other proteins. Interactions of histones and DNA are regulated through covalent PTMs to 
the histone tails [17, 18]. 
PTMs function to regulate chromatin dynamics by modifying histone-DNA interactions, altering 
higher order chromatin structure, and recruiting other chromatin factors [5]. There are multiple PTMs 
  
Figure 1 Levels of Chromatin Compaction.
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which regulate epigenetics, the most prevalent of which include acetylation, methylation, 
ubiquitination, sumoylation, phosphorylation, and ADP-ribosylation [19-24]. Histone methylation has 
been extensively studied, revealing that the location and degree of methylation on histone tail residues 
result in differential gene expression [25]. For example, the tri-methylation on lysine 27 of histone H3 
(H3K27me3) is associated with repressed chromatin, while H3K4me3 is considered an activating mark 
[26, 27]. To explain this dynamic nature of histone methylation, a current model proposes “reader” mol-
ecules which recognize specific methylated histone marks and subsequently recruit chromatin remodel-
ing enzymes and other non-histone proteins to further modify chromatin structure [18, 28]. 
 
1.2 Polycomb Group and EZH2 
A chromatin modifying complex currently under extensive study is the Polycomb Repressive 
Complex 2 (PRC2). PRC2 is a four-protein complex consisting of Embryonic Endoderm Development pro-
tein (EED), Suppressor of Zeste 12 (SUZ12), Enhancer of Zeste Homolog 2 (EZH2), and Retinoblastoma 
Associated Protein (RbAp46/48). EZH2 is the mammalian homolog of Drosophila Enhancer of Zeste [E(z)] 
[29, 30] and is responsible for catalyzing a tri-methyl group addition on lysine 27 of histone H3 
(H3K27me3) in human cells [31-33]. SUZ12 binds to EZH2, stabilizes its methyltransferase activity, and is 
required for the PRC2 complex to function [34]. EED stabilizes the complex by binding to the product of 
PRC2 catalysis, H3K27me3, and creating a positive feedback loop by further stimulating the complex 
[35]. RbAp46/48 is a histone chaperone known to bind histones H3 and H4, which further stabilizes the 
complex [36]. 
PRC2 has been shown to be a critical player in the repression of homeobox (HOX) genes in in-
sects and mammalian cells as well as in the regulation of differentiation in pluripotent cells [37]. The 
modulation of PRC2 expression and function has also been implicated in a variety of tumor types, includ-
ing multiple myeloma, follicular lymphoma, and esophageal, renal, breast, prostate and ovarian cancers 
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[38, 39]. The discovery of the importance of PRC2 in many cellular processes has led to a growing effort 
to determine the mechanisms of PRC2 recruitment to target genes. 
DNA binding domains among the polycomb complex proteins have yet to be identified in any 
species [35, 40]. In Drosophila, both PRC complexes are recruited to chromatin targets by DNA elements 
termed Polycomb Response Elements (PREs) (Figure 2), but these PREs are not commonly found in 
mammalian DNA, with only one human putative PRE described to date [41]. The PRE-binding protein in 
Drosophila, Pleiohomeotic (PHO), is related to the mammalian protein Yin-Yang 1 (YY1) [42-44], the only 
known mammalian homolog of the Drosophila PRE-binding proteins [41]. YY1 is a zinc-finger DNA (and 
RNA) binding protein which has been shown to both activate and repress gene transcription [45, 46]. In 
Xenopus embryos, YY1 has been found to associate with EED and is involved in neural differentiation 
[47]. Although these observations have led to speculation that YY1 has a similar function in mammalian 
cells as PHO in Drosophila [48], there is still little known about PRC1 and PRC2 tethering to target genes 
in mammalian cells [40].  Another protein with the potential to regulate EZH2 promoter binding is the 
Jumonji/ARID domain-containing protein 2 (JARID2), which has recently been shown to be a part of the 
PRC2 complex and to regulate PRC2 binding to target genes in human embryonic stem cells [49-53]. By 
studying the roles of YY1 and Jarid2 in PRC2 recruitment, we hope to elucidate novel mechanisms by 
which PRC2 is recruited to target promoters. 
1.3 Model System 
Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) molecules are es-
sential for the function of the immune system as they serve as critical signaling molecules for immune 
surveillance. MHC molecules present processed antigen to T cells of the immune system and thus allow 
for the recognition and elimination of foreign antigen [54]. There are two classes of MHC, Class I and 
Class II, which are expressed from 11 loci on chromosome 6 [55]. The variability of each loci among hu-
mans ranges from low to very high, and the possible inherited combinations of each lead to vast antigen 
6 
recognition diversity. MHC Class I (MHC I) molecules are present on the surface of all nucleated cells and 
present peptides from intracellular origin [56]. MHC I molecules bind the T cell receptor on CD8 positive 
T cells, resulting in CD8 T cell activation and initiation of an immune response to an intracellularly de-
rived antigen [57, 58]. MHC Class II (MHC II) molecules present peptides from extracellular origin, are 
constitutively expressed on antigen presenting cells (APCs) [56, 59] and are inducibly expressed on all 
nucleated cells in the presence of inflammatory cytokines, particularly interferon-γ (IFN-γ) [60-62]. MHC 
II molecules are important drivers of adaptive immune responses as they bind to CD4 positive T cells, 
and initiate inflammatory responses to extracellular antigens. 
MHC II expression is tightly controlled at the level of transcription by the master regulator, Class 
II Transactivator, or CIITA [63]. CIITA binds to the MHC II enhanceosome complex assembled on active 
MHC II promoters (Figure 3) and activates transcription of MHC II genes by recruiting RNA polymerase II 
and driving elongation of MHC II genes [64-68]. In the absence of CIITA, MHC II is not transcribed result-
ing in a loss of expression of MHC II [69]. Dysregulated expression of MHC II is implicated in multiple dis-
eases including the progression of cancer [70, 71] and initiation of autoimmune disease [72-74], thus it is 
imperative that we understand the mechanisms of CIITA expression. Because CIITA controls the expres-
sion of a universal immune molecule, it has four distinct promoters that are active in different cell types. 
Dendritic cells utilize promoter I for constitutive CIITA expression, B cells utilize promoter III for constitu-
tive CIITA expression, and promoter IV is responsible for inducible CIITA expressed through IFN-γ in nu-
cleated cells. Regulation of promoter II is less understood, and little is known about its function [75, 76]. 
Understanding the details of PRC2 and EZH2 involvement in transcriptional control of CIITA 
promoter IV (CIITA pIV) is of great significance to human health. EZH2 is implicated in the proliferation of 
many types of tumors and recent findings further demonstrate metastatic ability decreases in pancreatic 
cancer when EZH2 siRNA is used to suppress EZH2 expression [77]. MHC Class II expression has also 
been shown to be decreased in breast cancer, B-cell lymphoma, and Hodgkin lymphoma, which may  
  
Figure 3 The MHC II Promoter. The MHC II promoter consists of three DNA elements known as the X1, 
X2, and Y boxes which bind the components of the MHC II enhanceosome. Regulatory Factor X, 
AMP Response Element Binding Protein, and Nuclear Factor Y form the enhanceosome complex and 
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correlate with increased EZH2 binding [71, 78-80]. Once the mechanism of PRC2 recruitment is under-
stood in greater detail, modulation of MHC II gene expression may be achieved by blocking the specific 
recruitment of EZH2 to CIITA promoters using small molecule inhibitors. Broad applications include 
treatment of diseases involving dysregulated expression of MHC II. Here we detail the binding patterns 
of two putative PRC2 recruitment proteins, YY1 and Jarid2, and their effects on the expression of the 
inducible gene CIITA pIV. 
2     MATERIALS AND METHODS 
2.1 Cells 
HeLa (human epithelial) cells from ATCC (Manassas, VA) were cultured and passaged in Dulbec-
co Modified Eagle Medium (DMEM) (Mediatech, Inc., Herndon, VA) containing 10% Fetal Bovine Serum 
(FBS), 5 mM L-glutamine, and 5 mM penicillin-streptomycin at 37°C and 5% carbon dioxide. 
2.2 Antibodies 
Antibodies recognizing MYC-tag, FLAG-tag, and JARID2 were purchased from Abcam (Cam-
bridge, MA). Antibodies recognizing YY1, HA-tag, and HRP conjugated rabbit antibody were purchased 
from Santa Cruz (Santa Cruz, CA). Antibody recognizing H3K27me3 was purchased from Active Motif 
(Carlsbad, CA). Antibody recognizing EZH2 was purchased from Cell Signaling Technology (Danvers, MA) 
and HRP conjugated mouse antibody was purchased from Promega (Madison, WI). 
2.3 Plasmids 
The Myc-EZH2-pCDNA3 plasmid construct was described previously and was kindly provided by 
Jer-Tsong Hsieh [81]. The pCMV-HA-JARID2 construct was described previously [52]. Flag-YY1 was de-
scribed previously and was kindly provided by Myra Hurt [82]. The CIITA pIV luciferase construct was 
9 
described previously and was kindly provided by Bernard Mach [83]. The pcDNA control plasmid was 
described previously [84]. 
2.4 Primers 
Primers and probes for CIITA pIV and for the GAPDH promoter used in ChIP assays are as previ-
ously described [85-87] as well as primers and probes for CIITA pIV RNA, HLA-DRA RNA and GAPDH 
mRNA [86, 87]. Primers and the probe for Jarid2 mRNA expression are as follows: Jarid2 sense 
CACCGTCCTCCCCAATAACA, Jarid2 antisense CTCGAGACCAGCATGAGGTAGA, and Jarid2 probe 6 FAM-
AGGGTCCATCCTGCGTCACCTCG-TAMRA. 
2.5 siRNA Constructs and Transient Transfections 
Short interfering RNA duplexes (siRNA) pre-designed for YY1, JARID2 or scrambled All Star Con-
trol (Qiagen) were used to knock down expression of YY1 or JARID2. HeLa cells were transfected with 10 
nM of YY1 or JARID2 specific siRNA or All Star scrambled control sequence according to the HiPerfect 
Transfection Reagent protocol (Qiagen). Cells were lysed in NP40 cell lysis buffer with EDTA free com-
plete protease inhibitor (Roche) and were analyzed by western blot or RNA expression levels for effi-
ciency and specificity of knock down. 
2.6 Dual Luciferase Assay and Transient Transfection 
HeLa cells were plated at 1X10
5
 cells/well in 6-well tissue culture plates. Eight hours after plat-
ing, cells were transfected with 5µg of plasmid (CIITA-Luc, Flag-YY1, HA-Jarid2, Myc-EZH2, or pcDNA con-
trol) using Genejuice transfection regent (Novagen) according to manufacturer’s protocol. Each sample 
was also transfected with renilla luciferase as a control for protein levels. 18 hours after transfection, 
cells were treated with 500 U/mL IFN-γ and harvested 6 hours after stimulation as indicated. Cells were 
lysed using 1x lysis reagent (Promega), scraped from plates, and a dual luciferase was run per manufac-
turer’s protocol. 
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2.7 Co-Immunoprecipitation Assay and Transient Transfections 
HeLa cells were plated at a cell density of 8X10
5
 in 10cm
2
 tissue culture plates. Cells were al-
lowed to adhere to plate overnight. Cells were then transfected with 5µg of plasmid (Flag-YY1, HA-
Jarid2, Myc-EZH2, or pcDNA control) using GeneJuice (Novagen) per manufacturer’s protocol. Cells were 
harvested 18 hours later in NP40 lysis buffer with EDTA free complete protease inhibitor (Roche). Ly-
sates were centrifuged, normalized for protein concentration, and precleared with protein G beads 
(Pierce). After preclear, lysates were immunoprecipitated overnight with anti-Myc, anti-HA, or anti-Flag 
agarose beads (Sigma) or protein G mock bead control. For endogenous Co-IP, lysates were incubated 
with anti-Jarid2 antibody (Abcam) overnight, and the following morning incubated with Protein G beads 
for 1 hr. Bead-immune complexes were washed with dilute NP40 to remove background and subse-
quently eluted from beads and denatured by boiling for 5 minutes in Laemmli gel loading buffer with 
beta-mercaptoethanol (Bio-Rad). The collected supernatant was analyzed by western blot. 
2.8 Chromatin Immunoprecipitation (ChIP) 
HeLa cells were plated at a density of 2X10
6
 in 10cm
2
 tissue culture plates. Cells were treated 
with IFN-γ (500 U/mL) as indicated. After IFN-γ stimulation, cells were cross-linked with 37% formalde-
hyde. Crosslinking was stopped with 0.125M glycine and cells were harvested and lysed in cell lysis buff-
er (5 mM PIPES, 85 mM KCl) with IGEPAL (sigma) and e-complete protease inhibitors (Roche) for 15 
minutes on ice. Lysates were spun to isolate nuclei, and re-suspended in SDS lysis buffer with protease 
inhibitors and lysed on ice for 30 minutes. Lysates were then flash frozen twice in liquid N2 and subse-
quently sonicated in a water bath sonicator (3x 10 min cycles, 30 sec on/30 sec off) (Bioruptor, 
Diagenode). Lysates were pre-cleared for 1 hour at 4°C with salmon sperm DNA/protein A agarose 
beads (Millipore). After pre-clear, antibodies for indicated protein (or mock control) were added to each 
sample and incubated overnight with rotation at 4°C. Following overnight incubation, 
immunoprecipitation was performed with salmon sperm DNA/protein A which were added and incubat-
11 
ed for 1 hour with rotation at 4°C. Following immunoprecipitation, samples were washed for 3 minutes 
at 4°C with each of the following buffers as described previously: low salt buffer, high salt buffer, LiCl 
buffer, and 1X TE[88]. Samples were then eluted with SDS elution buffer and crosslinks were reversed 
overnight with 5M NaCl at 65°C; proteins were degraded using proteinase K (Invitrogen). 
Immunoprecipitated DNA was isolated using phenol:chloroform:isoamyl alcohol (Invitrogen) as per 
manufacturer’s protocol. Isolated DNA was analyzed by qPCR using primers and probes for indicated 
gene of interest. 
2.9 RNA Expression and Transient Transfections 
HeLa cells were plated at a density of 8X10
5
 cells per 10 cm
2
 tissue culture plate, and allowed to 
adhere to plate overnight. Cells were transfected with 5µg Myc-EZH2, Flag-YY1, HA-Jarid2, or pcDNA as 
indicated. 18 hours after transfection, cells were stimulated with IFN-γ as indicated and harvested with 
Qiazol RNA extraction reagent (Qiagen) per manufacturer’s protocol. An Omniscript Reverse Transcrip-
tion Kit (Qiagen) was used to generate cDNA from the extracted RNA. DNA generated was quantified by 
qPCR using primers and probes for CIITA pIV and GAPDH mRNA. 
2.10 RNA Expression in siRNA Treated Cells 
Cells were plated at a density of 8X10
5
 cells per 10 cm
2
 tissue culture plate. Cells were transfect-
ed with indicated siRNA construct as described above and incubated for 72 hours. Subsequently, an RNA 
extraction was performed as described above. 
3     RESULTS 
3.1 Ectopic Expression of EZH2, YY1 or Jarid2 Suppress CIITA-mediated MHC II mRNA Transcription 
Previous studies in our lab and others have demonstrated that the HLA-DRA and CIITA pIV genes 
are epigenetically regulated [89-91]. In particular, CIITA pIV is regulated by bivalent epigenetic marks 
12 
and its activation is characterized by a rapid loss of the suppressive modification H3K27me3 [89, 92]. 
The H3K27me3 histone mark is conferred by the histone methyltransferase EZH2, which is part of the 
larger Polycomb Repressive Complex 2 (PRC2) [31, 93, 94]. While PRC2 is known to be involved in gene 
silencing [31, 94], little is known of the mechanism by which PRC2 is recruited to target genes. Two pos-
sible recruitment proteins have been chosen as candidates for recruitment of this complex, YY1 and 
Jarid2. YY1 is the human homolog of a PRC2 recruitment protein discovered in Drosophila and Jarid2 has 
recently been implicated as a regulator of the PRC2 complex in human stem cells. To explore the effects 
of YY1 and Jarid2 on CIITA pIV, transient transfection was used to observe the effects of elevated ex-
pression of EZH2, YY1 and Jarid2 on the activity of the human CIITA promoter IV associated with a lucif-
erase reporter gene. HeLa cells were co-transfected with a CIITA pIV-luciferase reporter plasmid and 
either Myc-EZH2, Flag-YY1, or HA-Jarid2 plasmids. Cells were stimulated with the cytokine IFN-γ and in-
cubated for 6 hours to activate the CIITA pIV. Data is presented as fold increase in CIITA pIV luciferase 
activity, with increases measured relative to unstimulated sample.  
In order to determine if decreased CIITA promoter IV activity results in decreased CIITA mRNA 
levels, mRNA expression was measured in IFN-γ stimulated HeLa cells transiently transfected with Myc-
EZH2, Flag-YY1, or HA-Jarid2. RNA was extracted following transfection and 18 hours of IFN-γ stimula-
tion, and cDNA was generated from extracted RNA using a reverse primer specific for CIITA pIV mRNA in 
reverse transcription. Quantification of this cDNA was achieved by qPCR using primers and probes spe-
cific for CIITA pIV mRNA. Data is presented as relative CIITA mRNA molecules quantified using a standard 
curve in qPCR. Figures 4A and B indicate that when YY1 and Jarid2 proteins are expressed at levels high-
er than physiological norms, CIITA pIV activity is suppressed and results in a suppression of CIITA pIV 
mRNA expression. 
To determine if YY1 and Jarid2 suppression of  CIITA promoter activity and CIITA mRNA tra
scription  results in a decrease in MHC II mRNA, HeLa cells were transfected as described above and RNA 
was quantified using qPCR with primers and probe specific for MHC II mRNA. Si
  
Figure 4 Ectopic expression of EZH2, YY1, and Jarid2 suppress CIITA and MHC transcription. 
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into HeLa cells. Cells were harvested following 6 hours of IFN
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pIV. A western blot showing transfection efficiency is shown. (C) EZH2, YY1, and Jarid2 suppress 
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MHC II mRNA transcription were observed in cells overexpressing EZH2, YY1, or Jarid2 following 
18 hours of IFN-γ stimulation (Figure 4C). 
3.2 Binding Dynamics of EZH2, YY1 and Jarid2 at CIITA pIV 
We have previously observed that the suppressive histone modification H3K27me3 rapidly de-
creases at CIITA pIV following IFN-γ activation (Figure 5A) [91]. HeLa cells were subjected to a chromatin 
immunoprecipitation (ChIP) after 1 hour, 18 hours, or no treatment of IFN-γ to stimulate CIITA pIV activi-
ty. Antibody for H3K27me3 was used to immunoprecipitate the H3K27me3 modification. Data is pre-
sented as percent input of total precipitated DNA resulting from quantification using qPCR and primers 
and probe for CIITA pIV. Levels of H3K27me3 were also quantified at the GAPDH promoter to determine 
specificity (Figure 5B). 
If YY1 and Jarid2 are involved in recruitment of the PRC2 to CIITA pIV, it would be reasonable to 
assert that YY1 and Jarid2 binding at CIITA pIV likely follow the same trend as the H3K27me3 suppressive 
modification. To evaluate the binding profile of YY1 and Jarid2 at CIITA pIV, HeLa cells were subjected to 
a ChIP assay using antibodies for either YY1 (Figure 5C), Jarid2 (Figure 5D), or EZH2 (Figures 5C and 5D). 
Data is presented as percent input of total DNA. 
3.3 EZH2, YY1 and Jarid2 are Binding Partners 
If YY1 and Jarid2 are involved in recruitment of PRC2, it is likely these proteins interact with 
EZH2 (the active enzyme in the complex). To address this question, we examined the interactions using 
via co-immunoprecipitation. HeLa cells were transfected with either pcDNA control, Myc-EZH2, Flag-YY1, 
or HA-Jarid2. Cells were lysed, incubated with antibodies, and the immunoprecipitated lysate was trans-
ferred and probed with antibody for potential binding partners. In Figure 6A, YY1 immunoprecipitated 
with EZH2 in cells overexpressing tagged versions of these proteins. Figure 6B shows EZH2 
immunoprecipitated with endogenous Jarid2 in cells overexpressing t
YY1 
  
Figure 5 Binding Dynamics at CIITA pIV. 
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immunoprecipitation (ChIP) was performed using antibodies specific for H3K27me3. Associated DNA 
was analyzed by qPCR with primers and probes specific for CIITA pIV. (B) H3K27me3 levels at GAPDH are 
not affected by IFN-γ stimulation. To determine if IFN
ChIP assay was performed as previously described. Associated DNA was analyzed by qPCR using primers 
and probes for GAPDH. (C) EZH2 and YY1 dissociate fro
assay was performed as previously described using antibodies specific for YY1 and EZH2. (D) Jarid2 ass
ciation with CIITA pIV increases upon IFN
scribed with antibodies specific for Jarid2 and EZH2. Error bars in (B), (C), and (D) represent SEM of 
three independent experiments with p values shown as a result of students T Test. *p
***p≤0.001 ****p≤0.0001. Error bars in (A) are SEM of experim
data of all experiments performed.
action (Input). The control IgG values were 0.005 ± 0.001 and were subtracted from experimental va
ues. 
agged EZH2. Finally, in Figure 6
(A) H3K27me3 levels rapidly decrease upon IFN
-γ and were cross-linked, lysed, and sonicated. A chromatin 
-γ stimulation affects global H3K27me3 levels, a 
m the CIITA pIV upon IFN-γ stimulation. A ChIP 
-γ stimulation. A ChIP assay was performed as previously d
≤0.05 **≤0.01 
ental replicates and are representative 
 qPCR values were normalized to the total amount of DNA in the r
15 
C, 
-γ stimulation. 
o-
e-
e-
l-
  
Figure 6 EZH2, YY1, and Jarid2 are binding partners
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immunoprecipitated with Jarid2 in cells overexpressing tagged YY1 and Jarid2. Blots showing equal 
transfection efficiency are shown. 
3.4 Knocking Down YY1 or Jarid2 Significantly Decreases H3K27me3 and EZH2 Binding at CIITA pIV 
If YY1 and Jarid2 recruit PRC2, knocking down YY1 or Jarid2 may disrupt binding of PRC2 to the 
CIITA pIV and reduce H3K27me3 silencing. To explore the effects of knocking down YY1 and Jarid2 on 
polycomb recruitment, ChIP assays were performed to determine levels of EZH2 and H3K27me3 levels 
at CIITA pIV in cells treated with siRNA duplexes specific for YY1 or Jarid2. Cells were left untreated in 
order for the promoter to remain in an inactive state, with maximum PRC2 occupancy. In Figure 7A, we 
observed a significant decrease in EZH2 binding at the CIITA pIV in the presence of YY1 specific siRNA, as 
compared to a scrambled control siRNA. Mirroring this observation, there was a significant decrease of 
the suppressive histone modification, H3K27me3. Figure 7B is a western blot showing efficient and spe-
cific knockdown of YY1. Treating cells with siRNA specific to Jarid2 resulted in effects on EZH2 and 
H3K27me3 binding, with a significant decrease of EZH2 and H3K27me3 in the presence of Jarid2 siRNA 
(Figure 7C). mRNA expression assays were used to determine an efficient and specific knockdown of 
Jarid2. In Figure 7D, expression of Jarid2 mRNA significantly decreased with treatment of Jarid2 specific 
siRNA but did not affect GAPDH mRNA expression. 
3.5 Loss of Jarid2 Increases CIITA mRNA Expression 
As a loss of YY1 or Jarid2 showed decreased PRC2 recruitment to CIITA pIV, we next investigated 
the effect of YY1 and Jarid2 knockdown on CIITA mRNA expression. If YY1 or Jarid2 recruits PRC2, a loss 
of either protein would decrease the amount of PRC2 present at the CIITA pIV promoter, resulting in less 
epigenetic suppression and elevated levels of CIITA mRNA expression. To explore this possibility, cells 
were transfected using siRNA specific for YY1, Jarid2, or scrambled control siRNA and CIITA pIV mRNA 
expression was measured following the addition IFN-γ for 1, 2, 3, or 4 hours. As shown in figure 8A,  
  
Figure 7 Knockdown of YY1 or Jarid2 results in a significant loss of EZH2 
binding and H3K27me3
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Figure 8 Knockdown of Jarid2 significantly increases CIITA mRNA in the presence of IFN
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there was a significant increase in CIITA mRNA transcription at each timepoint of IFN-γ stimulation in the 
presence of Jarid2 siRNA as compared to scrambled control siRNA. In contrast, knockdown of YY1 failed 
to show a significant change in CIITA mRNA expression levels (Data not shown). Figure 8B shows the re-
sults of Jarid2 mRNA quantification to determine the efficiency of the Jarid2 siRNA. GAPDH mRNA ex-
pression was also measured to determine the specificity of Jarid2 siRNA duplexes in Figure 8C. 
4     DISCUSSION 
CIITA is the master regulator of MHC-II gene expression, and as such it modulates the levels of 
MHC-II in the cell [63]. CIITA is a tightly controlled gene that, when dysregulated, is capable of causing 
devastating immune related problems. Therefore, it is imperative that we understand the epigenetic 
mechanisms by which the CIITA gene is modulated. Indeed, as MHC II expression is controlled by CIITA 
[63], dysregulation of CIITA is correlated with a host of complications, from autoimmune diseases 
caused by an overexpression of MHC II [72-74] to tumor development implicated from decreased MHC II 
expression [70, 71].  
Epigenetic regulation plays an important role in CIITA pIV activation and has been shown to be 
effectively silenced by EZH2, the active member of the PRC2, and the silencing H3K27me3 modification 
it confers. Previous work from our lab demonstrated that knocking down EZH2 not only increases CIITA 
pIV mRNA transcription during IFN-γ stimulation, but also results in aberrant expression of silent CIITA 
pIV in the absence of cytokine stimulation. Because CIITA pIV is no longer silenced with knockdown of 
EZH2, it is likely that EZH2 and the PRC2 acts alone in the suppression of CIITA pIV, similar to its role in 
controlling gene expression during stem cell differentiation [95]. Results from these previous studies 
describe EZH2 as a crucial player in the silencing of CIITA pIV [90, 91]. 
To date, there is much speculation regarding the specific mechanism by which PRC2 is tethered 
to target chromatin. Many studies on PRC2 have focused on developmental genes and others that re-
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quire permanent or near-permanent silencing by PRC2 [50-53, 96-101]. Alternatively, our study aims to 
elucidate PRC2 mechanisms in a fluctuating system that requires rapid activation from a silent state and 
equally rapid deactivation in the absence of IFN-γ. Through information from current literature, two pro-
teins were chosen as candidates for involvement in the recruitment of PRC2 to CIITA pIV, YY1 and Jarid2. 
YY1 is the mammalian homolog of Pleiohomeotic (Pho), which is binds to conserved DNA elements in 
Drosophila DNA and is responsible for tethering the Drosophila equivalent of the PRC2 to these ele-
ments [42, 44]. Because of this homology, it is possible that YY1 has retained its PRC2 recruiting ability 
from Drosophila to mammalian cells. Similarly, Jarid2 has recently been found to associate with the 
PRC2 in Drosophila [102]. Likely in keeping with a semi-conserved function through evolution, Jarid2 co-
occupies chromatin sites with PRC2 and has been implicated as a major player in recruitment of PRC2 in 
mammalian cells [50-53, 99, 100]. We sought to determine if CIITA pIV was a novel co-occupation site 
for Jarid2 and PRC2, and if Jarid2 was responsible for regulating the binding of PRC2 to CIITA pIV. 
Both YY1 and Jarid2 have been implicated to be involved in PRC2 recruitment at some genes, 
but details remain obscure. To determine novel roles for these proteins at an inducible promoter, CIITA 
pIV, cells were transfected to ectopically express EZH2, YY1, or Jarid2. In cells that overexpress YY1 or 
Jarid2, there is an approximately 6 and 4 fold decrease in CIITA pIV luciferase activity, respectively, as 
compared to activity in cells transfected with the CIITA pIV-Luc construct only. Results from these re-
porter assays suggest that overexpression of EZH2 alone was insufficient to suppress CIITA pIV activity. 
However, when cells expressed higher levels of either YY1 or Jarid2, there was a significant decrease in 
the activity of the promoter (Figure 4A), suggesting CIITA pIV suppression. The same trend was observed 
when we measured levels of CIITA pIV mRNA and MHC II mRNA (Figure 4B and C). In contrast, the over-
expression of EZH2 had more of a negative effect on CIITA pIV and MHC II mRNA expression than on 
CIITA pIV luciferase activity, suggesting that EZH2 and the PRC2 require elements additional to the pro-
moter of CIITA pIV genes in order to bind and silence. 
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We have previously reported that following IFN-γ stimulation, EZH2 and H3K27me3 levels rapid-
ly decrease at CIITA pIV [91]. ChIP experiments indicate YY1 follows a similar trend of association with 
CIITA pIV (Figure 5C), albeit at lower levels. This observation supports the hypothesis of YY1 tethering 
PRC2 to CIITA pIV when silenced, and dissociating from the promoter once activated by IFN-γ. Interest-
ingly, Jarid2 significantly increases its presence at the CIITA pIV after IFN-γ stimulation (Figure 5D). This 
could be due to Jarid2 playing a role in the rapid activation of the promoter by recruiting other enzymes 
to regulate PRC2 removal. A recent study indicates that overexpression of Jarid2 in Drosophila results in 
a reduction of H3K27me3 [102]; it is possible Jarid2 acquired dual roles for PRC2 recruitment and re-
moval in mammalian cells. Further study is needed to elucidate mechanisms responsible for the inter-
esting binding pattern of Jarid2 at the CIITA pIV. 
We sought to determine whether YY1 and Jarid2 interact with the PRC2 in differentiated cells. 
Both YY1 and Jarid2 were found to associate with the PRC2 complex through co-immunoprecipitation. 
This study is the first to our knowledge to show YY1 exhibiting a physical association with EZH2 in human 
cells (Figure 6A). Additionally, YY1 is a physical binding partner of Jarid2 (Figure 6C), suggesting a novel 
YY1-Jarid2-PRC2 regulatory complex. Existence of this complex in differentiated cells may explain why 
the ablation of YY1 expression has limited effects on an inducible promoter but affects gene expression 
in undifferentiated myoblasts [48]. This complex is supported by previous studies linking YY1 to the 
PRC2 complex through the association of YY1 and EED, another member of the PRC2 complex. [41, 48, 
103, 104].  
Knocking down YY1 or Jarid2 results in decreased levels of EZH2 and PRC2 at CIITA pIV (Figure 7A 
and C), suggesting decreased polycomb recruitment when these proteins are expressed at sub-
physiological amounts. To corroborate this observation, CIITA mRNA levels increase when Jarid2 is 
knocked down (Figure 8A), which indicate Jarid2 as important in CIITA pIV suppression. In comparison, 
knockdown of YY1 failed to consistently increase CIITA pIV mRNA expression. It also possible that Jarid2  
  
Figure 9 Model: YY1 and Jarid2 action on Polycomb Repressive 
silenced through recruitment of PRC2 by the concurrent binding of YY1 and Jarid2 with EZH2 at the 
promoter. Upon activation, Jarid2 binding increases at CIITA pIV and possibly facilitates removal of 
PRC2 through interactions with YY1 or other unknown mechanisms.
Complex 2 at CIITA pIV.
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is more important in the regulation of this promoter, with YY1 having a more peripheral role in regulat-
ing biphasic gene expression. YY1 is strongly implicated in PRC2 recruitment to HOX genes and the inac-
tive X chromosome, two permanently silenced genes likely regulated in a different manner than the in-
ducible CIITA gene. This is supported by observations that YY1 has binding sites in a proposed human 
PRE among the HOX gene cluster [41], as well as associating with Xist, a long non-coding RNA (lncRNA) 
responsible for silencing the inactive X chromosome [105]. 
At this time, it is currently thought that PRC2 recruitment to target genes is controlled by a 
combination of recruitment proteins YY1, Jarid2, AEBP2, and adding further complexity, cell-type specif-
ic long non-coding RNA (lncRNA) which act as scaffolding for these recruitment proteins [50-53, 99, 100, 
103, 104, 106-108]. At this point, PRC2 recruitment to mammalian genes is poorly understood, and ob-
servations from the current study add to the complexity. Though knockdown of YY1 did not have a con-
clusive effect on CIITA pIV mRNA expression, YY1 remains a strong recruitment candidate in current lit-
erature because of its association with EED [103] and Xist [105]. Another lncRNA, HOTAIR, recruits PRC2 
to HOX genes to silence in a similar H3K27me3-mediated manner. LncRNA was initially investigated in 
the current study, however knockdown of HOTAIR proved to have no effect on the expression of CIITA 
pIV mRNA (Data not shown).  
It is likely that PRC2 recruitment is gene specific, and that CIITA pIV requires different machinery 
to regulate its rapid activation than genes such as HOX or the X chromosome that are permanently si-
lenced during development. Our study is the first to link YY1 and Jarid2 with epigenetic regulation of a 
dynamic promoter that requires tight control of rapid activation and silencing. Figure 9 depicts a model 
summarizing the interactions of the PRC2 with YY1 and Jarid2 at CIITA pIV. CIITA pIV in the silenced state 
shows interaction between YY1, Jarid2, and EZH2 and with the activation of CIITA pIV, increased 
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recruitment of Jarid2 may aid in the removal of the PRC2 through interaction of YY1 or through other 
unknown mechanisms. Further study is needed to define the fine-tuned mechanisms of each of these 
proteins’ involvement in the precise manipulation of CIITA pIV by PRC2.  
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